Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Diagn Microbiol Infect Dis ; 74(1): 39-42, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22749382

ABSTRACT

A retrospective matched case-control study of hospitalized patients with vancomycin-resistant Enterococcus (VRE) infection with reduced susceptibility to linezolid was performed in order to identify risk factors for this infection and describe patient outcomes. Forty-eight linezolid nonsusceptible VRE cases were identified between January 1, 2000, and September 30, 2008, and compared to 96 controls with linezolid-susceptible VRE, matched based on culture date and anatomic site of infection. Demographic, clinical and microbiological data were collected. On univariable analysis, risk factors for reduced linezolid susceptibility included allogeneic hematopoietic stem cell transplant and/or solid organ transplant (odds ratio [OR]: 2.63; 95% confidence interval [CI]: 1.13-6.15; P = 0.025), receipt of immunosuppressive medications (OR: 2.39; 95% CI: 1.08-5.29; P = 0.032) including corticosteroids (OR: 2.40; 95% CI: 1.03-5.58; P = 0.042) and noncorticosteroid immunosuppressives (OR: 2.31; 95% CI: 1.00-5.30; P = 0.049), and receipt of linezolid within 1 year prior to infection (OR: 34.50, 95% CI: 4.60-259.02; P < 0.001). On multivariable analysis, only receipt of linezolid within 1 year remained an independent risk factor for reduced linezolid susceptibility (OR: 31.84; 95% CI: 4.20-241.39; P < 0.001), although most patients with VRE with reduced linezolid susceptibility had not received linezolid in the year prior. Reduced linezolid susceptibility did not impact patient outcomes including clinical or microbiological cure, hospital length of stay, or all-cause mortality.


Subject(s)
Acetamides/pharmacology , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Enterococcus/isolation & purification , Gram-Positive Bacterial Infections/epidemiology , Oxazolidinones/pharmacology , Vancomycin/pharmacology , Adult , Aged , Aged, 80 and over , Case-Control Studies , Enterococcus/drug effects , Female , Gram-Positive Bacterial Infections/microbiology , Humans , Linezolid , Male , Microbial Sensitivity Tests , Middle Aged , Retrospective Studies , Risk Factors , Treatment Outcome , Young Adult
2.
J Pharm Pract ; 24(1): 44-60, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21507874

ABSTRACT

Shock states have multiple etiologies, but all result in hypoperfusion to vital organs, which can lead to organ failure and death if not quickly and appropriately managed. Pharmacists should be familiar with cardiogenic, distributive, and hypovolemic shock and should be involved in providing safe and effective medical therapies. An accurate diagnosis is necessary to initiate appropriate lifesaving interventions and target therapeutic goals specific to the type of shock. Clinical signs and symptoms, as well as hemodynamic data, help with initial assessment and continued monitoring to provide adequate support for the patient. It is necessary to understand these hemodynamic parameters, medication mechanisms of action, and available mechanical support when developing a patient-specific treatment plan. Rapid therapeutic intervention has been proven to decrease morbidity and mortality and is crucial to providing the best patient outcomes. Pharmacists can provide their expertise in medication selection, titration, monitoring, and dose adjustment in these critically ill patients. This review will focus on parameters used to assess hemodynamic status, the major causes of shock, pathophysiologic factors that cause shock, and therapeutic interventions that should be employed to improve patient outcomes.


Subject(s)
Hypovolemia/diagnosis , Hypovolemia/therapy , Shock/diagnosis , Shock/therapy , Animals , Disease Management , Fluid Therapy/methods , Hemodynamics/drug effects , Hemodynamics/physiology , Humans , Hypovolemia/physiopathology , Perfusion/methods , Shock/physiopathology , Shock, Cardiogenic/diagnosis , Shock, Cardiogenic/physiopathology , Shock, Cardiogenic/therapy , Vasoconstrictor Agents/pharmacology , Vasoconstrictor Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...